NYSE$PFE
Pfizer · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported record full-year results and provided full-year financial guidance.
Pfizer reported strong Q4 2022 results with revenues of $24.3 billion, reflecting 13% operational growth. Full-year 2022 revenues reached $100.3 billion, an all-time high, with reported diluted EPS of $0.87 for the quarter and $5.47 for the year.
- Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth.
- Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth.
- Fourth-Quarter 2022 Reported Diluted EPS of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS of $1.14, Up 45% Year-Over-Year.
- Provides Full-Year 2023 Revenue Guidance of $67.0 to $71.0 Billion and Adjusted Diluted EPS Guidance of $3.25 to $3.45.
Headline financials
Revenue & EPS history
Pfizer · Revenue · Quarterly
$24.3B
Revenue by segment
Pfizer · $24.3B total across 2 segments · Q4 2022
- Biopharma$23.9B+2.0%98.5%
- Pfizer CentreOne$368M-3.7%1.5%
Forward guidance
Pfizer provides full-year 2023 revenue guidance of $67.0 to $71.0 billion and adjusted diluted EPS guidance of $3.25 to $3.45. Excluding COVID-19 products, revenues are expected to grow 7% to 9% operationally.
Tailwinds
- Growth expected to be split among each of three categories: launch, acquired and in-line products
- Estimated proportion of U.S. population that receives a vaccine ~24%
- Estimated number of doses per vaccinated person per year, on average~1.3 doses
- Estimated Comirnaty market share - U.S.~64%
- Estimated total demand for Paxlovid - global*, excluding China (includes use of existing government supply)~17 million courses
Headwinds
- Company revenues are anticipated to be lower in 2023 than in 2022 due entirely to expected revenue declines for Pfizer’s COVID-19 products.
- Comirnaty revenues of approximately $13.5 billion, down 64% from actual 2022 results.
- Paxlovid revenues of approximately $8 billion, down 58% from actual 2022 results.
- The midpoint of the guidance range for Adjusted diluted EPS reflects a 49% operational decrease compared to 2022, primarily driven by anticipated lower revenues from COVID-19 products,
- Financial guidance for Adjusted diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-0.3%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.1%
Avg return
30 days after
50%
36 / 72 earnings
Positive
+8.1%
Q1 2024
Best reaction
-10.0%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -2.5% | -2.3% | |
| Q4 2025 | -3.3% | +2.1% | -0.2% | |
| Q3 2025 | -1.5% | -0.9% | +4.2% | |
| Q1 2025 | +3.2% | +5.0% | +1.7% | |
| Q4 2024 | -1.3% | -1.8% | +0.2% | |
| Q3 2024 | -1.2% | -2.7% | -10.5% | |
| Q2 2024 | -0.6% | -0.9% | -6.5% | |
| Q1 2024 | +8.1% | +9.9% | +11.9% | |
| Q4 2023 | -1.5% | -2.0% | -3.3% | |
| Q3 2023 | -0.1% | +2.3% | -0.3% | |
| Q2 2023 | -2.0% | -2.9% | -1.9% | |
| Q1 2023 | -1.9% | -1.8% | -3.0% | |
| Q4 2022 | +1.0% | +1.2% | -6.7% | |
| Q3 2022 | +1.1% | +1.4% | +9.7% | |
| Q2 2022 | -2.8% | -4.4% | -9.9% | |
| Q1 2022 | +2.7% | +1.4% | +9.0% | |
| Q4 2021 | -3.3% | -4.6% | -7.5% | |
| Q3 2021 | +2.7% | +11.4% | +21.5% | |
| Q2 2021 | +1.6% | +4.4% | +10.7% | |
| Q1 2021 | +0.4% | -0.6% | -2.2% | |
| Q4 2020 | -2.7% | -2.5% | -4.5% | |
| Q3 2020 | -6.5% | -6.4% | +1.5% | |
| Q2 2020 | +4.6% | +2.5% | +0.9% | |
| Q1 2020 | -0.5% | -1.8% | -0.4% | |
| Q4 2019 | -6.4% | -7.3% | -15.1% | |
| Q3 2019 | +3.2% | +3.0% | +3.6% | |
| Q2 2019 | -10.0% | -11.8% | -18.6% | |
| Q1 2019 | +3.0% | +4.5% | +5.8% | |
| Q4 2018 | +5.2% | +8.5% | +9.7% | |
| Q3 2018 | -0.4% | -0.7% | +5.3% | |
| Q2 2018 | +4.3% | +5.1% | +7.5% | |
| Q1 2018 | -4.7% | -4.8% | -1.9% | |
| Q4 2017 | -5.1% | -6.2% | -8.7% | |
| Q3 2017 | +0.3% | +1.1% | +3.2% | |
| Q2 2017 | -0.7% | +1.4% | +2.3% | |
| Q1 2017 | -0.9% | -0.9% | -3.2% | |
| Q4 2016 | +1.1% | +2.5% | +10.2% | |
| Q3 2016 | -3.4% | -5.4% | -0.8% | |
| Q2 2016 | -5.4% | -5.0% | -7.0% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -1.6% | — | — | |
| Q3 2015 | +3.8% | — | — | |
| Q2 2015 | +4.1% | — | — | |
| Q1 2015 | -0.9% | — | — | |
| Q4 2014 | -2.6% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +3.4% | — | — | |
| Q2 2011 | +4.8% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +0.5% | — | — | |
| Q1 2009 | -4.1% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q4 2007 | +0.4% | — | — | |
| Q4 2009 | +0.4% | — | — | |
| Q3 2008 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q4 2008 | +0.6% | — | — | |
| Q2 2008 | +0.6% | — | — | |
| Q2 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro